WO2023038112A1 - 薬剤溶出性の医療機器およびその製造方法 - Google Patents

薬剤溶出性の医療機器およびその製造方法 Download PDF

Info

Publication number
WO2023038112A1
WO2023038112A1 PCT/JP2022/033854 JP2022033854W WO2023038112A1 WO 2023038112 A1 WO2023038112 A1 WO 2023038112A1 JP 2022033854 W JP2022033854 W JP 2022033854W WO 2023038112 A1 WO2023038112 A1 WO 2023038112A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
drug
coat layer
medical device
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/033854
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
周平 松下
靖夫 黒崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to EP22867433.9A priority Critical patent/EP4382144A4/en
Priority to JP2023547004A priority patent/JPWO2023038112A1/ja
Publication of WO2023038112A1 publication Critical patent/WO2023038112A1/ja
Priority to US18/597,982 priority patent/US20240207492A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/041—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/02—Methods for coating medical devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/06—Coatings containing a mixture of two or more compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/08—Coatings comprising two or more layers

Definitions

  • the present invention relates to a drug-eluting medical device and a manufacturing method thereof.
  • a drug-eluting stent (hereinafter also referred to as "DES") is known as a drug-eluting medical device.
  • a DES is a device in which a drug, such as an immunosuppressant, is coated on the surface of a stent, which is a tubular structure that can be radially expanded and contracted.
  • a drug such as an immunosuppressant
  • an operator percutaneously introduces a catheter mounted with DES into the biological lumen and delivers it to the lesion.
  • DES When treating a lesion such as stenosis in a biological lumen such as a blood vessel using DES, an operator percutaneously introduces a catheter mounted with DES into the biological lumen and delivers it to the lesion. , DES.
  • the DES-coated drug infiltrates into the lesion and exerts its efficacy locally at the lesion.
  • Characteristics required for DES include high peel resistance between the drug and the stent, and sustained release of the drug.
  • drugs may delaminate from the stent surface during mounting, delivery, and expansion, which reduces drug loading.
  • the detached drug and thrombus formation originating from the detached drug obstruct the lumen of the body on the peripheral side, resulting in serious injury. can lead to Therefore, there is a demand for high peel durability between the drug and the stent.
  • sustained release it is often necessary to maintain efficacy for a long period of time when treating lesions.
  • a stent when expanded in a stenotic lesion in a blood vessel, the physical stimulation caused by stent expansion induces a biological reaction such as excessive proliferation of smooth muscle cells, causing restenosis. is said to start immediately after stent placement and reach a peak in several months to half a year.
  • the elution of the DES drug should be sustained for at least several months. Therefore, it is required that the elution of the drug should be sustained release.
  • Patent Document 1 as a medical device having a hydrophilic coating with excellent peeling durability, it can be applied to a wide variety of substrates such as metals, ceramics, and polymers, and is ideal.
  • the second coating layer may be configured in the form of a crosslinked copolymer formed via a crosslinking agent, and a functional group in the crosslinked copolymer and polydopamine are covalently bonded.
  • a pharmacological activity such as an antithrombotic agent, a hemostatic agent, an angiogenesis inhibitor, an angiogenic agent, an antibacterial agent, an antiproliferative agent, an antiproliferative agent, an anti-inflammatory agent, etc. It is disclosed that it may contain chemicals (drugs) that have Patent Document 1 mentions a stent as an example of a medical device to which the technology is applied.
  • the binding force of the drug with the polymer is small, and the drug is released early in any of the above cases.
  • the drug is incorporated inside the coating layer having a non-porous structure. Even if the polymer having a hydrophilic function in the second coating layer of Patent Document 1 is replaced with a polymer such as polylactic acid, which is well known as a polymer that supports a DES drug, the situation in which sustained release of the drug is difficult will change. do not have.
  • the present invention was made to solve the above-mentioned problems, and an object of the present invention is to provide a drug-eluting medical device in which drug elution is sustained release and whose coating layer is highly resistant to peeling, and a method for manufacturing the same.
  • a drug-eluting medical device that achieves the above object comprises a substrate, a first coating layer having a first polymer in which dopamine molecules or analogues thereof are self-oxidized and polymerized on the substrate, and the first coating layer. a second coat layer having a second polymer covalently bonded to the first polymer on the coat layer; and a third coat layer having a drug and a third polymer carrying the drug on the second coat layer. and a coat layer, wherein the second polymer and the third polymer form an interpenetrating polymer network structure.
  • a method for manufacturing a drug-eluting medical device that achieves the above object includes coating a first solution containing dopamine molecules or analogs thereof as a first coating material on a substrate, a first step of forming a first coat layer having a first polymer by polymerizing the coat material of; a second step of forming a second coat layer having a second polymer by applying a second solution containing the second solution and then heating or irradiating with light; a third step of applying a third solution containing a drug and a polymer as a coating material, followed by drying to form a third coating layer having a third polymer carrying the drug; characterized by having
  • the drug is supported by the third polymer in its original structure. It is said that it has medicinal efficacy and sustained drug elution, and that the third polymer and the second polymer form an interpenetrating polymer network structure, so that the coating layer has high peeling durability. It has characteristics.
  • FIG. 1 is a cross-sectional view of a base material and a coat layer of a drug-eluting medical device according to an embodiment
  • FIG. It is a TEM image of the cross section of the coat layer (the interface between the second coat layer and the third coat layer) of the example. It is a TEM image of the cross section of the coat layer (the interface between the second coat layer and the third coat layer) of the example. It is a TEM image of the cross section of the coat layer (the interface between the second coat layer and the third coat layer) of the comparative example.
  • the drug-eluting medical device 10 has a base material 20 and a coating layer 30.
  • the coat layer 30 includes a first coat layer 31 that coats the substrate 20, a second coat layer 32 that coats the first coat layer 31, and a third coat layer 32 that coats the second coat layer 32. and a coating layer 33 of The first coat layer 31 may coat the entire substrate 20 or may coat at least a portion of the substrate 20 .
  • the second coat layer 32 may coat the entire first coat layer 31 or may coat at least a portion of the first coat layer 31 .
  • the third coat layer 33 may coat the entire second coat layer 32, or may coat at least a portion thereof.
  • the coating layer 30 is formed on the outer surface of the stent, which is the base material 20, which is the tissue side of the biological lumen, and the inner surface of the biological lumen. of the inner surface and the side surface located between the outer surface and the inner surface, all the surfaces may be coated, but only any one or two surfaces may be coated. Moreover, the coat layer 30 coats all or at least a part of each surface, and the coat layers 30 on each surface may be formed integrally or separately.
  • At least a portion of the coating layer 30 such as the edge of the coating layer 30 in a direction parallel to the surface of the substrate 20 , necessarily between the substrate 20 and the first coating layer 31 , the first coating layer 31 and the first coating layer 31 .
  • the contact relationship between the two coating layers 32 or between the second coating layer 32 and the third coating layer 33 need not be satisfied.
  • the substrate 20 and the second coat layer 32 may be in contact with each other, or the third coat layer 33 may not be present on the second coat layer 32 .
  • the contact relationship between the substrate 20 and the first coating layer 31, between the first coating layer 31 and the second coating layer 32, and between the second coating layer 32 and the third coating layer 33 should be filled with at least part of the coat layer 30 .
  • the drug-eluting medical device 10 is a medical device that is used to bring a drug into the body tissue by contacting the body tissue.
  • the drug elution has sustained release properties, it is suitable for use in medical devices that come into contact with body tissues for a long time, and is more suitable for use in implantable medical devices that can be implanted in the body.
  • Examples of medical devices that come into contact with body tissues and are used to transfer drugs to body tissues include catheters such as balloon catheters, imaging catheters, ablation catheters, aspiration catheters, perfusion catheters, imaging catheters, and microcatheters, Sheath introducers, sheaths such as guiding sheaths, guide wires, medical patches such as anti-inflammatory analgesic patches, and the like.
  • Examples of implantable medical devices that can be implanted in the body include stents, stent grafts, artificial blood vessels, artificial bones, artificial heart valves, pacemakers, artificial joints, artificial hearts, indwelling catheters, embolization coils, aneurysm clips, thrombus filters, and the like. implantable insulin pumps, and the like.
  • the medical device is likely to be subjected to a force to peel the coating layer 30 before and after the drug-eluting medical device 10 according to the present embodiment is introduced to the target position in the body. It is suitable as the drug-eluting medical device 10 according to the embodiment.
  • the above-described implantable medical device that can be implanted in the body is likely to be subjected to a force that peels off the coat layer 30 before and after it is introduced into the target position in the body.
  • the drug-eluting medical device 10 is particularly suitable as the drug-eluting medical device 10 according to this embodiment.
  • the drug-eluting medical device 10 according to this embodiment is not limited to DES, and can also be applied to the medical devices described above.
  • the base material 20 of the drug-eluting medical device 10 is a fibrous protein such as metal, polymer, ceramic, silk or wool. At least a portion of substrate 20 may be composed of one or more of these materials.
  • metals that can be applied to the substrate 20 include stainless steel, cobalt-chromium alloys, platinum, platinum alloys, nickel-titanium alloys, titanium alloys, tantalum, tantalum alloys, gold, silver, iron, zinc, magnesium, niobium alloys, and the like. and are not limited to mixtures of
  • polymers that can be applied to the base material 20 include polyglycolic acid, polylactic acid, polycaprolactone, polydioxanone, polytetrafluoroethylene, trimethylene carbonate, polyethylene terephthalate, polybutylene terephthalate, polybutyl methacrylate, polycarbonate urethane, and polyether ether ketone.
  • polyolefin polyester, polyurethane, polyamide, polyether block amide, polyimide, polycarbonate, polyphenylene sulfide, polyphenylene oxide, polyether, silicone, polycarbonate, polymethacrylate, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyethylene co-vinyl acetate, polyethylene elastomer , polyvinyl chloride, rubber, silicone rubber, polyhydroxy acid, polyallylamine, polyallyl alcohol, polyacrylamide, polyacrylonitrile, acrylic oxide, polyacrylic acid, polymethacrylic acid, polystyrene, polyoxymethylene, phenol resin, aminoepoxy resin , cellulose-based plastics, and copolymers, derivatives, mixtures thereof, and the like, but are not limited thereto.
  • a copolymer means any polymer formed from two or more kinds of monomers. Also, these polymers may or may not be crosslinked. These polymers may also be blended
  • Ceramics that can be applied to the substrate 20 include, but are not limited to, silicone oxides, aluminum oxides, silica, hydroxyapatite, glass, calcium oxides, polysilanols, and phosphorous oxides. .
  • the surface of the substrate 20 of the drug-eluting medical device 10 may be smooth or rough.
  • a surface treatment technique such as a known cleaning treatment or plasma treatment may be applied to the surface of the base material 20.
  • the first coat layer 31 of the drug-eluting medical device 10 has a first polymer in which dopamine molecules or their analogues are self-oxidized and polymerized.
  • the first polymer is preferably polydopamine, which is a polymer formed by autooxidative polymerization of dopamine molecules, which are catecholamines.
  • polydopamine can be coated onto the surface of substrates of a wide variety of materials, with hydrogen bonding and coordination bonding to hydrophilic substrates, and ⁇ - ⁇ to hydrophobic substrates. It was discovered that it has high peel durability through hydrophobic interactions such as interactions, and secondary modification is also easy (Science, 2007, 318, pp.
  • the structure of the first polymer obtained by self-oxidation polymerization of a dopamine molecule or an analogue thereof in the present invention is not limited to a specific structure, and is a structure that can be assumed when a dopamine molecule or an analogue thereof undergoes self-oxidation polymerization. Everything.
  • the first coat layer 31 has a first polymer structure. That is, the first coat layer 31 may contain structures derived from other than dopamine molecules or analogues thereof. As an example in which the structure of the first polymer is present in a part of the coating layer, in Japanese Patent Application Publication No. 2016-513545, in order to improve the adhesion between the base material and polydopamine, dopamine molecules are covalently bonded to dopamine molecules.
  • a coated layer is disclosed which is polymerized by mixing molecules.
  • a portion of the coat layer has a polydopamine structure, and a structure derived from a molecule covalently bonded to a dopamine molecule is included in the coat layer as a structure derived from other than the dopamine molecule or its analogue.
  • first coating layer 31 may contain substances that do not covalently bond to dopamine molecules or analogs thereof. In this case as well, the first coat layer 31 at least partially has the structure of the first polymer, and is included in the technical scope of the present invention.
  • the first coat layer 31 may have a first polymer formed by self-oxidation polymerization of dopamine analogues, which are analogues of dopamine molecules. Also, the first coat layer 31 may have a first polymer formed by self-oxidation polymerization of a plurality of dopamine analogues. Also, the first coat layer 31 may have a first polymer formed by self-oxidation polymerization of dopamine molecules and one or two or more dopamine analogues.
  • Chemical formulas of dopamine analogues are, for example, chemical formulas described in paragraphs “0189” to “0193” and “0228” to “0230” of Patent Document 1.
  • the thickness of the first coat layer 31 is not particularly limited, it is, for example, 1 to 200 nm, preferably 5 to 150 nm, more preferably 10 to 100 nm, still more preferably 15 to 80 nm.
  • the thickness of the first coat layer 31 may be uniform or non-uniform.
  • the surface of the first coat layer 31 may be smooth or rough. The thickness of the first coat layer is measured by, for example, an atomic force microscope (AFM).
  • AFM atomic force microscope
  • the second coating layer 32 of the drug-eluting medical device 10 has a second polymer covalently bonded to the first polymer in which dopamine molecules or analogues thereof are self-oxidatively polymerized.
  • the second coat layer 32 is formed, for example, by placing a second polymer material on the first coat layer 31 and applying energy such as heat or light.
  • the second coat layer 32 may contain a polymerization initiator. When the second coating layer 32 is formed, covalent bonds between the first polymer and the second polymer are formed.
  • the covalent bond between the first polymer and the second polymer is, for example, the functional groups of the first polymer with abstracted hydrogen atoms on the surface of the first coating layer 31 and the functional groups of the first coating. It is formed by the functional groups of the second polymer in the second coating layer 32 which is in contact with the surface of the layer 31 .
  • the functional groups that form covalent bonds are determined by the materials and structures of the first polymer and the second polymer.
  • the radical initiator which is a polymerization initiator
  • the functional group forming the covalent bond on the substrate side is a functional group obtained by abstracting hydrogen atoms that can be abstracted from the surface of the substrate.
  • the mechanism of covalent bonding between the first polymer and the second polymer is not particularly limited.
  • the second polymer of the second coat layer 32 is preferably a crosslinked polymer in which a base polymer and a crosslinkable monomer are crosslinked. With such a configuration, a covalent bond is formed between the functional group of the crosslinkable monomer and the first polymer on the surface of the first coating layer 31, and the first coating layer 31 and the second coating are formed. The bonding strength with the layer 32 is improved, and the peel durability of the coat layer 30 is improved. In this case, since the functional groups of the base polymer do not necessarily have to be covalently bonded to the first polymer on the surface of the first coating layer 31, a wide variety of polymers can be selected as the base polymer.
  • a covalent bond may be formed between the functional group of the base polymer and the first polymer on the surface of the first coat layer 31 . Covalent bonds may also be formed between the functional groups of the crosslinkable monomer and the functional groups of the base polymer and the first polymer on the surface of the first coating layer.
  • the second polymer of the second coat layer 32 is a crosslinked polymer in which a base polymer and a crosslinkable monomer are crosslinked
  • examples of the base polymer include polyesters, aliphatic polyesters, polyanhydrides, polyorthoesters, and polycarbonates. , polyphosphazenes, polyphosphates, polyvinyl alcohols, polypeptides, polysaccharides, proteins, cellulose, and copolymers, derivatives and mixtures thereof.
  • aliphatic polyesters include polylactic acid, polycaprolactone, polyglycolic acid, polydioxanone, polybutyrolactone, polyvalerolactone, polyhydroxybutyric acid, polytrimethylene carbonate, and copolymers, derivatives, or mixtures thereof.
  • the form of the copolymer includes, but is not limited to, alternating copolymers, random copolymers, block copolymers, graft copolymers, and the like.
  • lactic acid (LA) which is a constituent monomer of polylactic acid (PLA)
  • PLA polylactic acid
  • PLLA poly-D-lactic acid
  • PDLLA poly-D,L-lactic acid
  • PDLLA poly-D,L-lactic acid
  • a polymer polymerized using lactic acid as a monomer is referred to as a polymer having lactic acid monomer units, regardless of the optical activity of the lactic acid used.
  • Lactic acid monomer units refer to the reacted form of lactic acid in the polymer.
  • Polymers having lactic acid monomer units include not only polylactic acid but also polymers polymerized using lactic acid and other monomers.
  • proteins such as collagen, fibrin and elastin, which are natural polymer materials, extracellular matrix components, other biological agents, derivatives thereof, or mixtures thereof may be used.
  • the base polymer has lactic acid monomer units. That is, the second polymer preferably has lactic acid monomer units.
  • the content of lactic acid monomer units in the base polymer is preferably 50 mol% or more (upper limit of 100 mol%), and is 70 mol% or more (upper limit of 100 mol%) of the total monomers constituting the base polymer. is more preferable.
  • the second polymer is preferably hydrophobic from the viewpoint that the desired effect of the present invention can be exhibited more effectively. Therefore, it is preferable that the base polymer is also hydrophobic.
  • the weight average molecular weight of the base polymer is preferably 100,000 to 1,000,000, more preferably 150,000 to 800,000, from the viewpoint of peel durability.
  • the weight average molecular weight is a value measured under the following measurement conditions by gel permeation chromatography (GPC) using polystyrene as a standard substance.
  • the cross-linkable monomer has a high affinity with the base polymer, and the surface of the first coat layer 31 Those having a strong bond with the first polymer are preferred.
  • the greater the polarity of the chemical structure connected to the terminal structure (CH 2 ⁇ CH— or CH 2 ⁇ C(CH 3 )— in the above example) having an unsaturated bond in the functional group the greater the reaction of the cross-linking monomer. sex grows.
  • the magnitude relationship of the polarity is (allyl group) ⁇ (acryloyl group) ⁇ (methacryloyl group) ⁇ (acrylamide group), so the reactivity of the crosslinkable monomer having an allyl group is that it has an acryloyl group or a methacryloyl group
  • the reactivity of the cross-linking monomer is lower than that of the cross-linking monomer, and the reactivity of the cross-linking monomer having an acrylamide group is often higher than that of the cross-linking monomer having an acryloyl group or a methacryloyl group.
  • the reactivity of the cross-linking monomers with methacryloyl groups is slightly lower than that of the cross-linking monomers with acryloyl groups, because the CH3 in the methacryloyl groups can be sterically hindered, but the reactivity of the cross-linking monomers with acryloyl groups is Equivalent to reactivity.
  • the number of functional groups is different in cross-linking monomers having the same type of functional groups, the greater the number of functional groups, the greater the reactivity.
  • (meth)acrylate means both acrylate, which is a crosslinkable monomer having an acryloyl group, and methacrylate (methacrylate), which is a crosslinkable monomer having a methacryloyl (methacryloyl) group.
  • Difunctional (meth)acrylates such as diethylene glycol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, 1,3-butylene glycol di(meth)acrylate, dicyclopentanyl di(meth)acrylate , glycerol di(meth)acrylate, 1,6-hexanediol di(meth)acrylate, neopentyl glycol di(meth)acrylate, tetraethylene glycol di(meth)acrylate, ethylene glycol di(meth)acrylate, polyethylene glycol di( meth)acrylate, diethylene glycol di(meth)acrylate, triethylene glycol di(meth)acrylate, 1,9-nonanediol di(meth)acrylate, 1,10-decanediol di(meth)acrylate and the like.
  • trifunctional (meth)acrylates include trimethylolpropane tri(meth)acrylate, pentaerythritol tri(meth)acrylate, and tetramethylolmethane (meth)acrylate.
  • tetrafunctional or higher (meth)acrylates include pentaerythritol tetra (meth) acrylate, ditrimethylolpropane tetra (meth) acrylate, dipentaerythritol penta/hexa (meth) acrylate, dipentaerythritol hexa (meth) acrylate, di pentaerythritol monohydroxy penta(meth)acrylate and the like.
  • crosslinkable monomers having an acrylamide group examples include N,N'-methylenebis(meth)acrylamide, N,N'-ethylenebis(meth)acrylamide, N,N'-hexamethylenebis(meth)acrylamide, N,N '-benzylidenebis(meth)acrylamide, N,N'-bis((meth)acrylamidomethylene)urea, N-[tris(3-(meth)acrylamidopropoxymethyl)methyl](meth)acrylamide (e.g., FOM-03006 ; N-[tris(3-acrylamidopropoxymethyl)methyl]acrylamide), N,N-bis(2-(meth)acrylamidoethyl)(meth)acrylamide (e.g., FOM-03007; N,N-bis(2- acrylamidoethyl)acrylamide), N,N'-[oxybis(2,1-ethanediyloxy-3,1-propanediyl)]bis(
  • crosslinkable monomers having an allyl group examples include triallyl trimellitate, triallyl pyromellitate, diallyl oxalate, triallyl cyanurate, and triallyl isocyanurate (TAIC).
  • the crosslinkable monomer is preferably a (meth)acrylate from the viewpoint of high bonding with the first polymer on the surface of the first coat layer 31, and a tetrafunctional or higher (meth)acrylate. is more preferable.
  • the base polymer has lactic acid monomer units and the crosslinkable monomer is (meth)acrylate.
  • the content ratio (weight ratio) of the crosslinkable monomer and the base polymer is not particularly limited, but the crosslinkable monomer is the base polymer.
  • the weight (100% by weight) of (100% by weight) it is preferably contained in an amount of 1% to 95% by weight, more preferably 5% to 90% by weight, and 10% to 90% by weight. % or less, even more preferably 30% to 90% by weight, and particularly preferably 30% to 70% by weight.
  • the crosslinkable monomer is preferably contained in an amount of 20% by weight or more and 80% by weight or less, and 30% by weight or more and 75% by weight or less based on the weight of the base polymer (100% by weight). more preferably contained.
  • the crosslinkable monomer is contained within the above range, an interpenetrating polymer network structure, which will be described later, can be efficiently formed, and the intended effects of the present invention can be exhibited more effectively.
  • crosslinkable monomer in the present invention is not limited to those having a vinyl group, an allyl group, an acryloyl group, a methacryloyl group, or an acrylamide group as functional groups.
  • crosslinkable monomers having other functional groups include maleimide compounds such as N-phenylmaleimide and N,N'-m-phenylenebismaleimide, and two or more triple bonds such as dipropargyl phthalate and dipropargyl maleate. and divinylbenzene.
  • the cross-linked polymer may be formed by cross-linking the base polymer and the cross-linking monomer, or may be formed by cross-linking the constituent monomers of the base polymer and the cross-linking monomer.
  • the structure of the crosslinked polymer formed by crosslinking the constituent monomers of the base polymer and the crosslinkable monomer also has a structure as a crosslinked polymer in which the base polymer and the crosslinkable monomer are crosslinked.
  • a cross-linked polymer obtained by cross-linking a base polymer and a cross-linking monomer is a polymer having a base polymer-constituting monomer unit and a cross-linking monomer unit in the molecular structure of the polymer.
  • the constituent monomer unit of the base polymer refers to the reacted form of the constituent monomer of the base polymer in the crosslinked polymer
  • the crosslinkable monomer unit refers to the reacted form of the crosslinkable monomer in the crosslinked polymer.
  • the crosslinked polymer may be composed of one type of base polymer or one type of base polymer constituent monomer and one type of crosslinkable monomer. It may be composed of a monomer.
  • the second polymer of the second coat layer 32 does not have to have a structure in which the base polymer and the crosslinkable monomer are crosslinked.
  • a polymer having one or more functional groups selected from a vinyl group, an allyl group, an acryloyl group, a methacryloyl group, or an acrylamide group is used as the second polymer, and this is used as the first polymer.
  • energy such as heat or light is applied to form the second coating layer 32, a covalent bond can be formed between the first polymer and the second polymer.
  • the number and positions of these functional groups in the second polymer are not limited.
  • the types of functional groups possessed by the second polymer are not limited to vinyl groups, allyl groups, acryloyl groups, methacryloyl groups, and acrylamide groups, and are functional groups capable of forming covalent bonds with the first polymer. It's all about base.
  • the second coating layer 32 should at least partially contain the second polymer that covalently bonds with the first polymer, and may contain additives other than the second polymer. Additives that were intentionally added or included unintentionally during the formation of the second coating layer 32 may form part of the second polymer in the form of covalent bonds.
  • the second coat layer 32 may contain a polymerization initiator.
  • Thermal polymerization initiators and photopolymerization initiators are known as polymerization initiators, but are not limited to either one. Moreover, you may use several polymerization initiators. Examples of photopolymerization initiators include benzyl dimethyl ketal, ⁇ -hydroxyalkylphenone, ⁇ -aminoalkylphenone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone, and the like. alkylphenone series, acylphosphine oxide series such as MAPO and BAPO, and oxime ester series. Moreover, you may use the commercial item of a polymerization initiator.
  • Examples of commercially available photopolymerization initiators include Irgacure 2959, 184, 1173, 907, 369E, 379EG, TPO and 819 manufactured by BASF.
  • the form of the polymerization initiator may change after applying energy, but the form of the polymerization initiator present in the second coat layer 32 may be the form after the change.
  • the crosslinking mechanism and polymerization mechanism of the second polymer are not limited. Moreover, the primary structure, secondary structure, and higher-order structure of the second polymer are not limited.
  • the thickness of the second coat layer 32 is not particularly limited, it is preferably 1 to 500 nm, preferably 5 to 400 nm, more preferably 10 to 350 nm, still more preferably 30 to 250 nm.
  • the thickness of the second coating layer 32 may be uniform or non-uniform.
  • the surface of the second coat layer 32 may be smooth or rough. The thickness of the second coat layer is measured by AFM, for example.
  • the third coating layer 33 of the drug-eluting medical device 10 has a drug and a third polymer carrying the drug on the second coating layer 32 .
  • the third polymer in the third coat layer 33 forms an interpenetrating polymer network structure with the second polymer in the second coat layer 32 .
  • An interpenetrating polymer network structure is also called an Interpenetrating Polymer Network (IPN), and means a structure in which one polymer network and another polymer network are entangled with each other without covalent bonds.
  • IPN Interpenetrating Polymer Network
  • the formation of an interpenetrating polymer network improves the bonding strength in each polymer network. Therefore, the entire polymer network after formation is difficult to separate into individual polymer networks before formation.
  • the third polymer in the third coat layer 33 and the second polymer in the second coat layer 32 form an interpenetrating polymer network structure, whereby the third coat layer 33 and the second coat layer 32, and the peel durability of the coat layer 30 is improved.
  • an interpenetrating polymer network structure can be confirmed, for example, by observing a cross section including the interface of each layer with a transmission electron microscope (TEM).
  • TEM transmission electron microscope
  • the coating layer 30 of the present invention may be embedded in a resin, and the resin-embedded sample may be thinly sliced using an ultramicrotome (Leica EM UC7) to obtain a sample in which the cross section of the coating layer 30 is exposed.
  • an interpenetrating polymer network structure formed between the second coat layer 32 and the third coat layer 33 can be confirmed.
  • the embedding resin known ones can be used, and for example, epoxy resin (Epon812), caprolactone (EVONIK C212), etc. can be preferably used.
  • TEM observation can be performed by the method described in Examples.
  • the interface between the coat layers 32 and 33 becomes unclear as a TEM image, and the brightness of the interface becomes uneven.
  • the brightness of the interface may differ from the brightness of the coat layers 32 and 33 . Therefore, when the above findings are obtained at the interface between the coat layer 32 and the coat layer 33 in the TEM image, it can be determined that an interpenetrating polymer network structure has been formed.
  • an interpenetrating polymer network structure can be determined by analyzing the layer structure using an optical analysis instrument such as Nano-FTIR.
  • an optical analysis instrument such as Nano-FTIR.
  • the cross section of the coating layer of the medical device may be directly confirmed, or the coating layer may be A component to be contained may be identified, and a cross section of a sample of a coating layer made of the identified component may be confirmed.
  • the interface between the second coat layer and the third coat layer becomes unclear.
  • a four-layer structure of "first coat layer + second coat layer + interpenetrating polymer network structure + third coat layer” or "first coat layer + interpenetrating polymer network Structure” can be observed like a two-layer structure.
  • the present invention may take either of these forms as long as the interpenetrating polymer network structure exists, and the effects of the present invention can be exhibited in either form.
  • the coat layer 30 when the coat layer 30 is produced, whether or not the third polymer and the second polymer form an interpenetrating polymer network structure can be visually confirmed, for example.
  • the third solution containing the third polymer when the third solution containing the third polymer is applied to the second coating layer 32 containing the second polymer, the third solution containing the third polymer becomes the second , and the second coat layer swells.
  • the color tone derived from the interference color of the coating film changes. From this, it can be determined that the third polymer and the second polymer have formed an interpenetrating polymer network structure.
  • the third polymer is preferably hydrophobic.
  • the hydrophobicity of the third polymer allows it to dissolve in the solvent.
  • a third solution obtained by dissolving a third polymer in a solvent is applied to the second coat layer, and the third solution permeates the second coat layer, thereby forming a second polymer. of the coating layer swells. This forms an interpenetrating polymeric network between the third polymer and the second polymer.
  • the third solution also contains the drug, when the third polymer and the second polymer form an interpenetrating polymer network structure, A drug may be incorporated into the network.
  • the second polymer is also preferably hydrophobic.
  • the medical device of the present invention can demonstrate peeling durability under the usage environment because the third polymer is hydrophobic.
  • the third polymer is hydrophilic (e.g., polyethylene glycol, etc.)
  • the third coat layer and the second coat layer swell under the usage environment, and the peel durability of the coat layer is maintained. Therefore, the sustained release properties of the drug cannot be exhibited.
  • the third polymer and the second polymer are hydrophobic, the third coat layer and the second coat layer do not swell under the usage environment, and the coat layer of peeling durability can be maintained.
  • the second polymer and the third polymer have identical monomer units.
  • Such a configuration improves the affinity between the second polymer and the third polymer, forming an interpenetrating polymer network between the second coating layer 32 and the third coating layer 33. is promoted, the bonding strength between the second coat layer 32 and the third coat layer 33 is increased, and the peel durability of the coat layer 30 is improved.
  • the monomer units of the second polymer and the third polymer refer to reacted forms of the constituent monomers of each polymer.
  • the second and third polymers have identical monomeric units if each polymer is synthesized using the same constituent monomers regardless of optical activity. Also, in preferred embodiments, the second polymer and the third polymer have identical monomeric units in at least a portion of each.
  • Drugs in the third coating layer 33 include, for example, immunosuppressive agents, anticancer agents, antibiotics, antirheumatic agents, antithrombotic agents, HMG-CoA reductase inhibitors, ACE inhibitors, calcium antagonists, and antihyperlipidemic agents.
  • immunosuppressants include sirolimus, everolimus, pimecrolimus, zotarolimus, biolimus, tacrolimus, azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, and gusperimus.
  • anticancer agents include paclitaxel and docetaxel.
  • Antibiotics include, for example, mitomycin, adriamycin and the like.
  • Antithrombotic agents include, for example, aspirin, ticlopidine, argatroban, and the like.
  • HMG-CoA reductase inhibitors include, for example, cerivastatin.
  • ACE inhibitors include, for example, quinapril.
  • Examples of calcium antagonists include hifedipine.
  • Antihyperlipidemic agents include, for example, probucol and the like.
  • Integrin inhibitors include, for example, AJM300.
  • Antiallergic agents include, for example, tranilast.
  • Antioxidants include, for example, ⁇ -tocopherol.
  • GPIIb/IIIa antagonists include, for example, abciximab.
  • Examples of retinoids include all-trans retinoic acid.
  • Examples of lipid-improving drugs include eicosapentaenoic acid and the like.
  • Antiplatelet agents include, for example, clopidogrel and the like.
  • Anti-inflammatory agents include, for example, dexamethasone, prednisolone, and the like.
  • Hemostatic agents include, for example, thrombin and collagen.
  • Angiogenesis inhibitors include, for example, sunitinib.
  • Angiogenic agents include, for example, RGD protein and
  • the third polymer in the third coat layer 33 carries and slowly releases the drug.
  • the drug be present dispersed within a non-porous polymer for sustained release of the drug. Even if the drug is dispersed within the polymer, if the polymer is porous, the drug can be released early through the pores of the polymer. For this reason, it is preferred that the third polymer is non-porous.
  • the release rate of a drug from a drug-carrying polymer depends on the diffusion rate of the drug in the polymer in the case of non-biodegradable polymers, and the rate of drug diffusion in the polymer in the case of biodegradable polymers. In addition to the diffusion rate, it depends on the degradation rate of the polymer.
  • the diffusion rate of the drug within the polymer correlates with the flexibility of the polymer. Therefore, it is known that the drug release rate can be controlled by adjusting the flexibility and degradation rate of the polymer.
  • polymer surfaces induce foreign body reactions in living organisms, and such foreign body reactions are known to be a cause of inflammatory reactions.
  • a biodegradable polymer from which the polymer-derived inflammatory response disappears in the future is preferred over a non-biodegradable polymer from which the polymer-derived inflammatory response may persist chronically.
  • the third polymer is preferably a biodegradable polymer that is non-porous and has appropriate flexibility and degradation rate.
  • a polymer being non-porous refers to a polymer that does not have pores visible by SEM.
  • a polymer in which gaps of about 0.1 ⁇ m can be confirmed by SEM observation is regarded as porous.
  • Such third polymers include polylactic acid, polycaprolactone, polyglycolic acid, polydioxanone, polybutyrolactone, polyvalerolactone, polyhydroxybutyric acid, polytrimethylene carbonate and copolymers, derivatives or mixtures thereof. is mentioned.
  • These polymers are hydrophobic and non-porous biodegradable polymers.
  • a polymer having a lactic acid monomer unit is preferable as the third polymer because its decomposition products are metabolites in the body, so it has excellent biosafety and has an excellent drug release rate.
  • PLLA, PDLA, PDLLA, poly(lactic acid- ⁇ -caprolactone) which is a copolymer of lactic acid and ⁇ -caprolactone, and poly(lactic acid-glycolic acid) which is a copolymer of lactic acid and glycolic acid are preferable.
  • a copolymer of lactic acid and another monomer by adjusting the ratio of lactic acid and another monomer, the flexibility can be changed and the release rate can be adjusted.
  • the third polymer is not limited to these.
  • the third polymer in one embodiment, is poly(lactic acid- ⁇ -caprolactone), a copolymer of lactic acid and ⁇ -caprolactone.
  • caprolactone is softer than other polymers, inclusion of caprolactone as the third polymer makes it possible to impart flexibility to the third coat layer, thereby improving peel durability.
  • the second polymer and the third polymer preferably have the same monomer units, more preferably lactic acid monomer units.
  • the second polymer and the third polymer have the same monomer unit, the affinity between the second polymer and the third polymer is improved, and the second coat layer The formation of an interpenetrating polymer network between 32 and the third coating layer 33 is promoted to increase the bonding strength between the second coating layer 32 and the third coating layer 33, and the coating layers The peel durability of 30 is improved.
  • the presence of lactic acid monomer units in the third polymer improves biosafety and sustained release of drug elution.
  • the content of lactic acid monomer units in the third polymer is preferably 50 mol% or more (upper limit of 100 mol%), and 70 mol% or more (upper limit of 100 mol%) of the total monomers constituting the third polymer. %) is more preferred.
  • the weight average molecular weight of the third polymer is preferably 100,000 to 1,000,000, more preferably 150,000 to 800,000, from the viewpoint of peel durability.
  • the third polymer satisfactorily forms an interpenetrating polymer network structure with respect to the base polymer that constitutes the second polymer.
  • the content of the third polymer is preferably the same as that of the base polymer constituting the second polymer, and the content ratio (weight ratio) of the third polymer and the base polymer is 2:1 to 1:2. and more preferably 1.5:1 to 1:1.5.
  • the third polymer has lactic acid monomer units, and the crosslinkable monomer is contained in an amount of 5% by weight or more and 90% by weight or less with respect to 100% by weight of the base polymer. In a more preferred embodiment of the present invention, the third polymer has lactic acid monomer units, and the crosslinkable monomer is contained in an amount of 30% by weight or more and 90% by weight or less with respect to 100% by weight of the base polymer. . In a further preferred embodiment of the present invention, the third polymer has lactic acid monomer units, and the crosslinkable monomer is contained in an amount of 30% by weight or more and 70% by weight or less with respect to 100% by weight of the base polymer. .
  • the third coat layer 33 should at least partially contain the drug and the third polymer, and may contain other additives.
  • Additives include, for example, dissolution aids such as dimethyl tartrate and diethyl tartrate, which improve the diffusion rate of the drug in the polymer, but the additives possessed by the third coating layer 33 are not limited to these. .
  • the primary structure, secondary structure, and higher-order structure of the third polymer are not limited.
  • the drug in the third coat layer 33 is preferably dispersed uniformly, but is not limited. Moreover, the drug present in each dispersed region may form a cluster in which a plurality of drug molecules are gathered. Also, the third coating layer 33 may have nanoparticles, and the drug may be present as being encapsulated in the nanoparticles.
  • the nanoparticle material is, for example, a copolymer of lactic acid and glycolic acid.
  • the third coating layer 33 it is formed without applying heat or light energy in order to prevent the original structure of the drug from changing into a related substance and losing its efficacy. Therefore, the drug is carried by the third polymer in its original structure and does not form a covalent bond with the third polymer. Further, part of the drug may migrate into the second coat layer 32 during the process of forming the third coat layer 33 .
  • the thickness of the third coat layer 33 is not particularly limited, it is 0.1 to 200 ⁇ m, preferably 1 to 150 ⁇ m, more preferably 5 to 100 ⁇ m, still more preferably 10 to 80 ⁇ m.
  • the thickness of the third coat layer 33 may be uniform or non-uniform.
  • the surface of the third coat layer 33 may be smooth or rough. The thickness of the third coat layer is measured, for example, with a laser microscope.
  • the crosslinkable monomer is a crosslinkable monomer having a (meth)acrylate group with a functionality of 2 or more (preferably tetrafunctional or more).
  • the third polymer has lactic acid monomer units; In this case, the covalent bond between the first coat layer and the second coat layer and the interpenetrating polymer network structure between the second coat layer and the third coat layer are well formed. The intended effect of the invention can be further exhibited.
  • the crosslinkable monomer is a crosslinkable monomer having a (meth)acrylate group with a functionality of 2 or more (preferably tetrafunctional or more) (e.g., 1,4-butanediol diacrylate, pentaerythritol tetraacrylate or dipentaerythritol hexaacrylate);
  • the third polymer is preferably polylactic acid or poly(lactic acid- ⁇ -caprolactone).
  • the crosslinkable monomer is a crosslinkable monomer having a (meth)acrylate group with a functionality of two or more (preferably a functionality of four or more) (for example, , 1,4-butanediol diacrylate, pentaerythritol tetraacrylate or dipentaerythritol hexaacrylate);
  • the third polymer is poly-L-lactic acid or poly(lactic- ⁇ -caprolactone).
  • the crosslinkable monomer when the base polymer of the second polymer has a caprolactone unit, the crosslinkable monomer has a bifunctional or more (preferably tetrafunctional or more) (meth)acrylate, allyl group or acrylamide group.
  • the third polymer has lactic acid monomer units or caprolactone units.
  • the crosslinkable monomer is a crosslinkable monomer having a bifunctional or more (preferably tetrafunctional or more) (meth)acrylate, allyl group or acrylamide group; is poly-L-lactic acid or poly(lactic- ⁇ -caprolactone).
  • Another coat layer may be provided on the third coat layer 33 .
  • Other coat layers include, for example, a function of suppressing the release rate of the drug in the third coat layer 33 to further impart sustained release properties, and a drug other than the drug in the third coat layer 33,
  • the third coat layer 33 may have a function of assisting the efficacy of the medicine in the third coat layer 33 .
  • Materials for other coat layers are not particularly limited.
  • the method for manufacturing the drug-eluting medical device 10 includes dopamine molecules or analogs thereof as the first coating material on the base material (hereinafter also referred to as “including the first coating material”).
  • a second solution containing a certain polymer and/or monomer (hereinafter also referred to as “containing a second coating material”) is applied and then heated or irradiated to form the second coating layer 32.
  • Step 2 and applying a third solution containing a drug and a polymer as a third coating material (hereinafter also referred to as "containing the third coating material") onto the second coating layer 32; and a third step of forming the third coat layer 33 by drying thereafter.
  • a first solution containing dopamine molecules or analogs thereof, which is a first coating material is applied onto a base material.
  • a first solution containing dopamine molecules or analogues thereof, which is a first coating material is applied to the base material, and the first coating material is polymerized to form the first coating layer 31.
  • the first coat layer 31 formed by such a process is polydopamine or a polydopamine-like polymer, it has high peeling durability between the base material 20 and the first coat layer 31, and another Additional coats of material are facilitated.
  • the material used as the base material and the dopamine molecule analogue are not particularly limited, the materials exemplified in the description of the first coat layer 31 can be applied.
  • the solvent of the solution containing the first coating material is not particularly limited as long as the first coating material is soluble.
  • the solution containing the first coating material may also contain additives such as buffers.
  • the first coating material may be in the form of a hydrate, hydrochloride, or the like of a dopamine molecule or an analogue thereof.
  • the method of applying the first solution containing the first coating material to the substrate is not particularly limited.
  • a preferred coating method is dip coating.
  • the solvent for the first solution for example, water, a buffer solution, a solvent used for the third solution described later, or the like is used.
  • the solvent is preferably water or a buffer solution, more preferably a Tris-HCl buffer solution.
  • the content of the first coating material is preferably 0.01 to 30% by mass, more preferably 0.05 to 10% by mass, relative to the total weight of the first solution. More preferably, it is 0.01 to 5% by mass.
  • Dopamine molecules or their analogues are known to self-oxidize and polymerize, and when a base material is immersed in a solution containing these, they self-oxidize and polymerize on the surface of the base material, forming a thin film on the surface of the base material. is formed.
  • the first coating layer 31 may be formed by applying energy to the base material to polymerize the first solution containing the first coating material by another method.
  • the first coat layer 31 may be formed by adding steps such as washing, drying, and annealing after the film formed by polymerizing the first coat material is formed. By adding this to the annealing process, the peel durability between the substrate and the first coat layer 31 can be improved.
  • the temperature and time for annealing are not particularly limited.
  • a second solution containing a polymer and/or a monomer as a second coating material is applied onto the first coating layer 31, and then heated or irradiated with light to form a second coating.
  • a layer 32 is formed.
  • the second coating material is a combination of a base polymer and a crosslinkable monomer; a combination of a constituent monomer of the base polymer and a crosslinkable monomer; a polymer having a functional group capable of covalent bonding with the first coat layer 31;
  • a combination of As the base polymer and the crosslinkable monomer the materials exemplified in the description of the second coat layer 32 can be applied.
  • the second coating material After applying a second solution containing these second coating materials on the first coating layer 31, the second coating material is crosslinked and/or polymerized by heating or light irradiation to form a second coating layer. 32 is formed, a covalent bond is formed between the first coat layer 31 and the second coat layer 32, and peel durability between the first coat layer 31 and the second coat layer 32 improves. That is, in one embodiment, the second step is to apply a second solution containing a polymer or / and a monomer as a second coating material on the first coating layer, and then heat or irradiate This forms a second coating layer having a second polymer covalently bonded to the first polymer.
  • the solvent for the second solution containing the second coating material is not particularly limited as long as the second coating material is soluble.
  • the solvent for the second solution for example, the solvent used for the third solution, which will be described later, is similarly used.
  • the solution containing the second coating material may contain additives such as a polymerization initiator and a buffer.
  • the second coating material may be in the form of a hydrate, hydrochloride, or the like.
  • the content ratio of the solvent and the second coating material is not particularly limited, but it is preferably 10 to 800 mL, and 20 to 600 mL with respect to 1 part by weight of the second coating material. more preferably 100 to 500 mL.
  • the method of applying the second solution containing the second coating material in the second step is not particularly limited.
  • steps such as washing, drying, and annealing may be added before heating or light irradiation or after heating or light irradiation.
  • a drying step is added before heating or light irradiation. If the drying step is added after heating or light irradiation, the second coat material is crosslinked and/or polymerized while containing the solvent, so that the second coat layer 32 becomes porous and the second coat layer 32 becomes porous.
  • the mechanical strength of the layer and the bonding strength with the first coat layer 31 and/or the third coat layer 33 may decrease, and the peel durability of the coat layer 30 may decrease. Therefore, by adding a drying step before heating or light irradiation, the second coat layer 32 becomes non-porous, and the peel durability of the coat layer 30 is improved. Drying conditions are not particularly limited.
  • conditions such as heating temperature, heating time, wavelength of irradiated light, and integrated amount of light are not particularly limited during heating or light irradiation.
  • energy can be applied by a method other than heating or light irradiation as long as it can promote cross-linking and/or polymerization.
  • a third solution containing a drug and a polymer, which is the third coating material is applied onto the second coating layer 32, and then dried to form the third coating layer 33. It is formed. Materials exemplified in the description of the embodiment of the third coat layer 33 can be applied to the drug and polymer of the third coat material.
  • a third solution containing these third coating materials is applied onto the second coating layer 32 and then dried to form a third coating layer 33 in which the drug is carried in the polymer in its original structure and is slowly released. is formed, an interpenetrating polymer network is formed between the second coating layer 32 and the third coating layer 33, and delamination between the second coating layer 32 and the third coating layer 33 Improves durability.
  • the third step after applying the third solution containing the drug and the polymer as the third coating material, it is dried without heating or light irradiation.
  • the risk of heat or light breaking chemical bonds within the drug is eliminated, and analogues that alter the original structure of the drug are not produced. Therefore, there is no loss of efficacy, and there is no risk of side effects caused by related substances.
  • what is heated or irradiated with light does not necessarily fall outside the technical scope of the present invention. Heating or light irradiation at a weak level that does not cause changes in the original structure of the drug is also included in the technical scope of the present invention. That is, in the third step, after applying the third solution containing the drug and the polymer, which is the third coating material, the drug is dried without heating or light irradiation at a level that causes a change in the original structure of the drug. do.
  • the second coat material is soluble in a solvent of a third solution containing the third coat material, and in the third step, the third coat material is When the third solution containing the material is applied onto the second coat layer 32, the second coat layer 32 swells.
  • the polymer which is the material of the third coat, easily penetrates into the second coat layer 32, and the interpenetration height between the second coat layer 32 and the third coat layer 33 increases. The formation of a molecular network structure is promoted, the bonding strength between the second coat layer 32 and the third coat layer 33 is increased, and the peel durability of the coat layers is improved.
  • the solvent for the third solution containing the third coating material is not particularly limited as long as the second coating material and the third coating material are soluble.
  • solvents include dimethylacetamide, dimethylformamide, tetrahydrofuran, cyclohexanone, acetone, acetonitrile, propylene glycol monomethyl ether, methyl butyl ketone, methyl ethyl ketone, diethyl ketone, ethyl acetate, n-butyl acetate, dioxane, chloroform, dimethyl sulfoxide, dimethyl Formamide, benzene, toluene, xylene, hexane, cyclohexane, pentane, heptane, octane, nonane, decane, decalin, isobutyl acetate, isopropyl acetate, diacetone alcohol, benzyl alcohol, 1-butanone, N-methylpyr
  • the content ratio of the solvent and the third coating material is preferably 10 to 100 mL, more preferably
  • the third solution containing the third coating material may contain additives such as buffers.
  • the third coating material may be in the form of a hydrate, hydrochloride, or the like.
  • the method of applying the third solution containing the third coating material is not particularly limited. Moreover, the drying conditions for drying after applying the third solution containing the third coating material are not particularly limited.
  • the present invention includes the following aspects and forms.
  • a substrate a first coating layer having a first polymer in which a dopamine molecule or an analog thereof is self-oxidized and polymerized on the substrate, and the first polymer on the first coating layer a second coat layer having a covalently bonded second polymer, and a third coat layer having a drug and a third polymer carrying the drug on the second coat layer, wherein A drug-eluting medical device, wherein the second polymer and the third polymer form an interpenetrating polymer network structure.
  • At least part of the second coating material is soluble in the solvent of the third solution, and the third solution is applied onto the second coating layer in the third step
  • the peeling durability which is the effect of the drug-eluting medical device that achieves the object of the present invention, will be described below using the following examples.
  • the following examples illustrate part of the configuration of the drug-eluting medical device that achieves the object of the present invention.
  • the configuration of the drug-eluting medical device that achieves the object of the present invention is not limited to these examples.
  • the third solution contains only the third polymer, so the coat layer does not contain the drug.
  • the third polymer is non-porous, long-term sustained drug release is possible, so those skilled in the art will understand that the samples obtained in this example have long-term sustained release properties. It is possible.
  • ⁇ Preparation of solution containing second coating material (second solution)>
  • the structure of the coating layer obtained is the structure of the example, and when PVA is used as the polymer in the third solution, the resulting coat
  • the layer configuration is that of the comparative example.
  • ⁇ Preparation of first coat layer> A plate material of SUS304 (size: length 150 mm ⁇ width 70 mm ⁇ thickness 0.8 mm) was immersed in an aluminum vat filled with the first solution. After standing for 24 hours, the sample was removed and the surface was rinsed with distilled water. Then, it was dried at room temperature in the air for 2 hours. After that, it was left to stand on a hot plate heated to 200° C. in the atmosphere for 5 minutes to perform annealing treatment. The thickness of the obtained first coating layer was 40 nm as a result of measurement by AFM (measurement equipment: Bruker Nano Surfaces, Dimension Icon).
  • the polymer formed on the first coat layer will be referred to as the first polymer.
  • ⁇ Preparation of the second coat layer> The sample on which the first coating layer was formed was immersed in an aluminum vat filled with the second solution and immediately taken out. Then, it was dried in the air at room temperature for 1 hour. After that, it was dried in a vacuum oven at 40° C. for 24 hours. The dried sample was placed in a polyethylene bag, and while the inside of the bag was replaced with nitrogen, ultraviolet light with a wavelength of 365 nm was irradiated from the outside of the bag so that the integrated light amount was 300 J/cm 2 .
  • the sample was taken out of the bag, immersed in an aluminum vat filled with chloroform, and washed with an ultrasonic cleaner for 10 minutes to remove residual components such as unreacted monomers and photopolymerization initiators.
  • a second coating layer was prepared for each of the 74 types of second solutions. The thickness of the obtained second coating layer was measured by AFM (measurement equipment: Bruker Nano Surfaces, Dimension Icon). (Samples with bracketed ratings) were 50 nm to 100 nm thick, and non-bracketed samples were 150 nm thick.
  • the polymer formed on the second coat layer will be referred to as the second polymer.
  • the polymer formed on the third coat layer will be referred to as the third polymer.
  • the third polymer (PLLA, LCL7525, DLCL9010, PVA) was observed by SEM (S-3400N, Hitachi High-Tech) after exposing the cross section of the sample by ion milling (IM4000Plus, Hitachi High-Tech). The absence of possible voids was observed, confirming that the third polymer was non-porous.
  • the ⁇ index of the position of the interface where peeling occurred'' if no interference color derived from the second coat layer is observed on the peeled surface, it is set to "A”, and the second coat layer on the peeled surface. If the interference color derived from changes, or if the interference color derived from the second coat layer is partially observed on the peeled surface, it is designated as "B”, and the interference color derived from the second coat layer is observed on the peeled surface. When observed in the same manner as in the formation of the second coat layer, it was rated as "C".
  • the peel durability index is "1" or more, it can be determined that an interpenetrating polymer network structure is formed.
  • peel durability index is "0"
  • the “0C” evaluation indicates that an interpenetrating polymer network structure is not formed, and evaluations other than “0C” (e.g., “1C” etc.) are interpenetrating This indicates that a polymer network structure is formed.
  • Table 1 summarizes the results of the peel durability test for each sample, using the indices shown in Table 1 for evaluation of peel durability, and using the indices shown in Table 2 for the results of specifying the position of the interface where peeling occurred.
  • Table 6 “( )” (evaluation enclosed in parentheses) indicates that part of the second coat layer disappeared during ultrasonic cleaning with chloroform during the preparation of the second coat layer.
  • “Dry” indicates test results in air, and "Wet” indicates test results in water.
  • any of PLLA, LCL7525, PDLLA and PCL as the base polymer of the second polymer
  • 1,4-BDDA, PETA It was found that coated layers formed from any of DPEHA, TAIC, and FOM-03006; and PVA as the third polymer did not have sufficient peel durability.
  • the peel durability was generally higher than when TAIC or FOM-03006 was used. Therefore, in embodiments of the present invention, it is more preferred that the crosslinkable monomer is an acrylate.
  • the reason for this is that the reactivity of the acryloyl group, which is the functional group of acrylate, is good, the covalent bond between the first coat layer and the second coat layer is sufficient, and the acrylate and the base polymer used this time Since the compatibility with is good, a sufficient crosslinked structure is formed between the crosslinkable monomer and the base polymer, and the polymer component is retained even during ultrasonic cleaning with chloroform, so the third coat layer It is thought that a sufficient interpenetrating polymer network structure could be formed between Moreover, when the crosslinkable monomer is methacrylate, the reactivity of the methacryloyl group, which is a functional group, is equivalent to that of the acryloyl group. Therefore, in the embodiment of the present invention, it is more preferable that the crosslinkable monomer is (meth)acrylate.
  • the peel durability was generally higher than when the base polymer was PCL.
  • the third polymer and the base polymer have lactic acid monomer units.
  • the base polymer having lactic acid monomer units has a higher affinity with the third polymer than the base polymer having no lactic acid monomer units. It is believed that the properties were good and facilitated the formation of an interpenetrating polymer network between the second and third coating layers.
  • the peel durability was generally higher when the third polymer was LCL7525 or DLCL9010 than when the third polymer was PLLA.
  • the presence of caprolactone monomer units in both the base polymer and the third polymer improves the affinity between the two, and the interpenetration height between the second coat layer and the third coat layer. It is conceivable that the formation of a molecular network structure was promoted.
  • the affinity between the second polymer and the third polymer is improved by having the same monomer unit in the second polymer and the third polymer, not limited to the lactic acid monomer unit and/or the caprolactone monomer unit. and promotes the formation of an interpenetrating polymer network between the second and third coating layers, increasing the bonding strength between the second and third coating layers. , suggesting that the peel durability of the coat layer is improved.
  • the crosslinkable monomer is PETA or DPEHA
  • the base polymer has lactic acid monomer units
  • the crosslinkable monomer is 5% by weight or more and 90% by weight based on the weight of the base polymer (100% by weight).
  • the peeling durability was generally high.
  • the third polymer and the base polymer have lactic acid monomer units
  • the crosslinkable monomer is a tetrafunctional or higher acrylate
  • the crosslinkable monomer is PETA or DPEHA
  • the base polymer has lactic acid monomer units
  • the crosslinkable monomer is 30% by weight or more and 90% by weight based on the weight of the base polymer (100% by weight).
  • the peeling durability was generally high.
  • the third polymer and the base polymer have lactic acid monomer units
  • the crosslinkable monomer is a tetrafunctional or higher acrylate
  • the third polymer and the base polymer have lactic acid monomer units, the crosslinkable monomer is a tetrafunctional acrylate, the base polymer further has caprolactone monomer units, and the crosslinkable monomer is the weight of the base polymer (100 weight %), and the third polymer and the base polymer have lactic acid monomer units, the crosslinkable monomer is a pentafunctional or higher acrylate, and the base polymer has a caprolactone monomer unit, and the crosslinkable monomer is contained in an amount of 5% by weight or more and 30% by weight or less with respect to the weight of the base polymer (100% by weight). Preferred in form.
  • the crosslinkable monomer is PETA or DPEHA
  • the base polymer has lactic acid monomer units
  • the crosslinkable monomer is 30% by weight or more and 70% by weight based on the weight of the base polymer (100% by weight). % or less, the peeling durability was generally high.
  • the third polymer and the base polymer have lactic acid monomer units
  • the crosslinkable monomer is a tetrafunctional or higher acrylate
  • the covalent bond between the first coat layer and the second coat layer is sufficiently formed, and the interpenetration height between the second coat layer and the third coat layer is reduced. It is suggested that the formation of molecular network structure is promoted.
  • the crosslinkable monomer is PETA or DPEHA
  • the base polymer has lactic acid monomer units
  • the crosslinkable monomer is contained at 90% by weight relative to the weight of the base polymer (100% by weight)
  • the interface at which delamination occurs is between the second coat layer and the third coat layer
  • the crosslinkable monomer is contained at 30% by weight or more and 70% by weight or less with respect to the weight of the base polymer (100% by weight)
  • the ratio of the crosslinkable monomer in the second coat layer increased, and the second coat layer when the third solution was applied on the second coat layer It is conceivable that the swellability of the coating layer was lowered, and the formation of the interpenetrating polymer network between the second and third coating layers was relatively
  • the third solution is more concentrated than the second when it is contained at 70% by weight or less. It was confirmed that the second coat layer had a low swelling property when applied on the coat layer. The position of the interface where peeling occurred is inside the second coat layer, and the cross-linkable monomer is contained at 30% by weight or more and 70% by weight or less with respect to the weight of the base polymer (100% by weight). As a factor for the lower property, it is considered that the second coat layer became brittle due to an increase in the ratio of the crosslinkable monomer in the second coat layer.
  • the third polymer and the base polymer have lactic acid monomer units, the crosslinkable monomer is a tetrafunctional acrylate, and the crosslinkable monomer is 70% by weight or more and 90% by weight with respect to the weight of the base polymer (100% by weight). % or less, the third polymer and the base polymer have lactic acid monomer units, the crosslinkable monomer is a pentafunctional or higher acrylate, and the crosslinkable monomer accounts for the weight of the base polymer (100% by weight).
  • the peel durability is generally higher than when the content is 70% by weight or more and 90% by weight or less, which is preferable in the embodiment of the present invention.
  • Second solution As a base polymer, L-lactic acid/ ⁇ -caprolactone copolymer (LCL7525, BMG Co., Ltd., BioDegmer (registered trademark) LCL (75:25), molecular weight 570,000); 0.05 g of dipentaerythritol hexaacrylate (DPEHA) as a cross-linking monomer; 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1 - A second solution was prepared by mixing 0.01 g of propanone (IRGACURE 2959); and 20 ml of chloroform.
  • L-lactic acid/ ⁇ -caprolactone copolymer (LCL7525, BMG Co., Ltd., BioDegmer (registered trademark) LCL (75:25), molecular weight 570,000); 0.05 g of dipentaerythritol hexaacrylate (DPEHA) as a cross-linking monomer; 2-hydroxy-1-[4-(2-hydroxy
  • sample 2 For sample 2, DLCL9010 was used as the polymer, chloroform was used as the solvent, and the polymer was dissolved in chloroform at room temperature.
  • sample 3 PVA was used as the polymer, water was used as the solvent, and the polymer was dissolved in water at 80°C.
  • ⁇ Preparation of film sheet made of second coating material> The second solution was poured into a PFA petri dish with a diameter of 75 mm without air bubbles, and air-dried overnight at room temperature to obtain a cast film. Next, the obtained film was placed in a polyethylene bag, and in a state where the inside of the bag was replaced with nitrogen, ultraviolet light with a wavelength of 365 nm was irradiated from the outside of the bag so that the integrated light amount was 3000 mJ/cm 2 to form a film. was peeled off from the petri dish to obtain a film sheet made of the second coating material.
  • the thickness of the film sheet made of the second coating material was 200 to 300 ⁇ m as a result of measurement with a thickness gauge (model: 547-360, manufactured by Mitutoyo Co., Ltd.). The thickness was 3 to 6 ⁇ m as a result of measurement with a laser microscope (VK-X200, KEYENCE).
  • the composition of each coating layer of Samples 1 to 3 obtained is shown in Table 7 below.
  • Samples 1 to 3 having the coating layer with the composition shown in Table 7 above were embedded in resin.
  • Samples 1 and 2 of Examples used epoxy resin (Epon812) as the embedding resin, and Sample 3 of Comparative Example used caprolactone (EVONIK C212) as the embedding resin.
  • the hydrophobic polymer caprolactone was selected as the embedding resin for sample 3 in order to avoid the PVA used as the third polymer from dissolving in the epoxy resin (Epon 812).
  • FIGS. 2 is a TEM image of sample 1
  • FIG. 3 is a TEM image of sample 2
  • FIG. 4 is a TEM image of sample 3.
  • an interpenetrating polymer network structure was formed by the second polymer and the third polymer at the interface between the second coat layer and the third coat layer, and a heterogeneous polymer structure was formed.
  • IPN in FIGS. 2 and 3 indicates a region where an interpenetrating polymer network is believed to be formed.
  • Table 8 shows the results of a peel durability test on Samples 1 and 2.
  • the peel durability test method is the same as the method described above.
  • sample 2 uses base polymer LCL7525 and crosslinkable monomer DPEHA as the second polymer described in Table 4, and DLCL9010 (solvent type of the third solution: CHCl 3 ) as the third polymer. is the same as the system.
  • the third solution for making the third coated layer had a similar concentration between the second and third coated layers, whether using CHCl 3 or HFIP solvent as the solvent. It was confirmed that an interpenetrating polymer network was formed. Thus, similar interpenetration between the second and third coating layers was observed whether CHCl 3 or HFIP was used as the solvent for the third solution to make the third coating layer. It was confirmed that a polymer network structure was formed.
  • the drug is supported by the third polymer in its original structure, so that the drug has the intended efficacy, and the drug is eluted in a sustained release manner. Since the polymer forms an interpenetrating polymer network structure with the second polymer, there is an effect that the peel durability of the coat layer is high.
  • the second polymer and the third polymer may be characterized by having the same monomer units.
  • the affinity between the second polymer and the third polymer is improved, and an interpenetrating polymer network structure is formed between the second coat layer and the third coat layer.
  • the bonding strength between the second coat layer and the third coat layer increases, and the peel durability of the coat layers improves.
  • the second polymer may be characterized by being a crosslinked polymer obtained by crosslinking a base polymer and a crosslinkable monomer.
  • a covalent bond is formed between the functional group of the crosslinkable monomer and the first polymer, and the bonding strength between the first coat layer and the second coat layer is improved. , the peel durability of the coat layer is improved.
  • the functional groups of the base polymer do not necessarily have to be covalently bonded to the first polymer, allowing a wide variety of polymers to be selected as the base polymer.
  • the third polymer may be characterized by having lactic acid monomer units.
  • the second polymer and the third polymer may be characterized by having lactic acid monomer units.
  • the affinity between the second polymer and the third polymer is improved, and an interpenetrating polymer network structure is formed between the second coat layer and the third coat layer.
  • the bonding strength between the second coat layer and the third coat layer increases, and the peel durability of the coat layers improves.
  • biosafety and sustained release of drug elution are improved.
  • the base polymer may have lactic acid monomer units, and the crosslinkable monomer may be (meth)acrylate.
  • the (meth)acrylate may be characterized by being tetrafunctional or higher.
  • the third polymer and the base polymer have lactic acid monomer units
  • the crosslinkable monomer is a tetrafunctional or higher acrylate
  • the crosslinkable monomer accounts for the weight (100% by weight) of the base polymer. It may be characterized by being contained in an amount of 5% by weight or more and 90% by weight or less.
  • the third polymer and the base polymer have lactic acid monomer units, the crosslinkable monomer is a tetrafunctional or higher acrylate, and the crosslinkable monomer is 30% with respect to the weight (100% by weight) of the base polymer. It may be characterized by being contained in an amount of not less than 90% by weight.
  • the first coat layer and the second coat layer are more likely to be formed than when the crosslinkable monomer is contained in an amount of 5% by weight or more and less than 30% by weight with respect to the weight of the base polymer (100% by weight).
  • a covalent bond with the coat layer is formed more easily, and the peel durability of the coat layer is improved.
  • the third polymer and the base polymer have lactic acid monomer units, the crosslinkable monomer is a tetrafunctional or higher acrylate, and the crosslinkable monomer is 30% with respect to the weight (100% by weight) of the base polymer. It may be characterized by being contained in a weight % or more and 70 weight % or less.
  • the second coat layer and the second coat layer are more effective than the case where the crosslinkable monomer is contained in more than 70% by weight and 90% by weight or less with respect to the weight of the base polymer (100% by weight).
  • An interpenetrating polymer network structure is easily formed with the coat layer of No. 3, and the peel durability of the coat layer is improved.
  • drug-eluting stents are subject to a force that peels off the coating layer, and drug elution that suppresses the biological reaction that causes restenosis lasts for at least several months. Therefore, it is particularly suitable as a drug-eluting medical device of the present invention.
  • the drug-eluting medical device may be characterized as a drug-eluting stent.
  • a method for manufacturing a drug-eluting medical device comprises coating a substrate with a first solution containing dopamine molecules or analogs thereof as a first coating material, a first step of forming a first coat layer having a first polymer by polymerizing the coat material of; a second step of forming a second coat layer having a second polymer by applying a second solution containing the second solution and then heating or irradiating with light; a third step of applying a third solution containing a drug and a polymer as a coating material, followed by drying to form a third coating layer having a third polymer carrying the drug; characterized by having
  • the first coat layer composed of polydopamine or a polydopamine-like polymer is formed in the first step.
  • a second coat layer is formed by cross-linking and/or polymerizing the second coat material, and a covalent bond is formed between the first coat layer and the second coat layer. be done.
  • a third coating layer is formed in which the drug is supported on the polymer for sustained release, and an interpenetrating polymer network structure is formed between the second coating layer and the third coating layer. is formed, and the drug, which is the third coating material, is supported on the polymer without losing its original efficacy. Therefore, it is possible to manufacture a drug-eluting medical device in which drug elution is sustained release without losing the original efficacy of the drug, and the coat layer has high peeling durability.
  • the second coating material is soluble in the solvent of the third solution, and in the third step, when the third solution is applied onto the second coating layer, Secondly, it may be characterized in that the second coat layer swells.
  • the polymer constituting the second coating layer and the polymer constituting the third coating layer formed by the manufacturing method described above are the second polymer and It may have the characteristics that the third polymer had.
  • the method for manufacturing a drug-eluting medical device includes: (1) the second polymer and the third polymer have the same monomer unit; (2) the third polymer contains lactic acid; (3) the second polymer and the third polymer have lactic acid monomer units; (4) the second polymer is a crosslinked polymer in which a base polymer and a crosslinkable monomer are crosslinked; (5) In (4) above, the base polymer has lactic acid monomer units, and the crosslinkable monomer is (meth)acrylate; (6) In (5) above, the (meth)acrylate is tetrafunctional or higher; and/or (7) in (4) to (6) above, the third polymer has lactic acid monomer units, and the crosslinkable monomer accounts for 100% by weight of the base polymer with respect to 5% by weight or more and 90% by weight or less; By having the second polymer and the third polymer having the above characteristics, the peel durability of the coat layer is improved.
  • the method for manufacturing a drug-eluting medical device described above may be characterized by being a method for manufacturing a drug-eluting stent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Materials For Medical Uses (AREA)
PCT/JP2022/033854 2021-09-10 2022-09-09 薬剤溶出性の医療機器およびその製造方法 Ceased WO2023038112A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22867433.9A EP4382144A4 (en) 2021-09-10 2022-09-09 Drug-eluting medical device and production method therefor
JP2023547004A JPWO2023038112A1 (https=) 2021-09-10 2022-09-09
US18/597,982 US20240207492A1 (en) 2021-09-10 2024-03-07 Drug-eluting medical device and method for producing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-147558 2021-09-10
JP2021147558 2021-09-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/597,982 Continuation US20240207492A1 (en) 2021-09-10 2024-03-07 Drug-eluting medical device and method for producing the same

Publications (1)

Publication Number Publication Date
WO2023038112A1 true WO2023038112A1 (ja) 2023-03-16

Family

ID=85506418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/033854 Ceased WO2023038112A1 (ja) 2021-09-10 2022-09-09 薬剤溶出性の医療機器およびその製造方法

Country Status (4)

Country Link
US (1) US20240207492A1 (https=)
EP (1) EP4382144A4 (https=)
JP (1) JPWO2023038112A1 (https=)
WO (1) WO2023038112A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230263648A1 (en) * 2022-02-21 2023-08-24 Boston Scientific Scimed, Inc Drug elution for implantable medical device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015154925A (ja) * 2014-01-17 2015-08-27 株式会社日本ステントテクノロジー 耐食性に優れたステント
JP2016508776A (ja) 2013-02-04 2016-03-24 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ 基板用コーティング
JP2016513545A (ja) 2013-03-14 2016-05-16 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ 表面のコーティング
WO2021006291A1 (ja) * 2019-07-09 2021-01-14 大塚メディカルデバイス株式会社 薬剤溶出型ステント

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508776A (ja) 2013-02-04 2016-03-24 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ 基板用コーティング
JP2016513545A (ja) 2013-03-14 2016-05-16 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ 表面のコーティング
JP2015154925A (ja) * 2014-01-17 2015-08-27 株式会社日本ステントテクノロジー 耐食性に優れたステント
WO2021006291A1 (ja) * 2019-07-09 2021-01-14 大塚メディカルデバイス株式会社 薬剤溶出型ステント

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRICOUT NICOLAS; CHAI FENG; SOBOCINSKI JONATHAN; HERTAULT ADRIEN; LAURE WILLIAM; UNG ALEXANDRE; WOISEL PATRICE; LYSKAWA JOEL; BLAN: "Immobilisation of an anti-platelet adhesion and anti-thrombotic drug (EP224283) on polydopamine coated vascular stent promoting anti-thrombogenic properties", MATERIALS SCIENCE AND ENGINEERING C, ELSEVIER SCIENCE S.A., CH, vol. 113, 13 April 2020 (2020-04-13), CH , XP086159434, ISSN: 0928-4931, DOI: 10.1016/j.msec.2020.110967 *
SCIENCE, vol. 318, 2007, pages 426 - 430

Also Published As

Publication number Publication date
JPWO2023038112A1 (https=) 2023-03-16
EP4382144A1 (en) 2024-06-12
US20240207492A1 (en) 2024-06-27
EP4382144A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
CA2571302C (en) Drug-eluting articles with improved drug release profiles
US20100028403A1 (en) Medical devices for therapeutic agent delivery
US20060147491A1 (en) Biodegradable coating compositions including multiple layers
US20100023116A1 (en) Biocorrodible implant with a coating containing a drug eluting polymer matrix
US20060198868A1 (en) Biodegradable coating compositions comprising blends
US7442721B2 (en) Durable biocompatible controlled drug release polymeric coatings for medical devices
WO2009020797A2 (en) Polymers for implantable devices exhibiting shape-memory effects
EP2268329B1 (en) Implantable medical device coatings with improved mechanical stability
WO2010141173A1 (en) Terpolymers containing lactide and glycolide
JP2007535368A (ja) 埋め込み型用具上のコーティングの熱特性及び機械的特性を調節する方法
CN1964748A (zh) 用于生物活性剂的涂料组合物
CN101346156B (zh) 具有附加在电移植底涂层上的可生物降解释放层的药物洗脱支架
JP2008528212A (ja) 制御された薬物送達および調節された生体適合性のための多孔質高分子領域を有する医療機器
US20200230296A1 (en) Implantable Medical Instrument Made of Iron-Based Alloy and Manufacturing Method Therefor
JP2007185494A (ja) 両親媒性コポリマー組成物
JP5611036B2 (ja) エラストマー性ブロックコポリマーコーティングを有する埋込型医療装置
US20240207492A1 (en) Drug-eluting medical device and method for producing the same
WO2019013101A1 (ja) 自己拡張型ステントおよびその製造方法
Nguyen et al. Biomaterials and stent technology
US20160074562A1 (en) Drug eluting stent with a biodegradable release layer attached with electro-grafted primer coating
CN111601625B (zh) 自膨型支架及其制造方法
WO2005097224A1 (ja) ポリマー被覆型ステント
WO2008059975A1 (fr) Matériau inhibant la coagulation du sang, matériau de revêtement et éléments à demeure in vivo faits à l'aide du matériau, et procédé de traitement
WO2026070552A1 (ja) 生体内留置用ステント、ステントデリバリーシステムおよび生体内留置用ステントの製造方法
Lee et al. “Hot-dog-string” drug-eluting degradable stents for treating stenosis in tortuous arteries

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22867433

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023547004

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2022867433

Country of ref document: EP

Effective date: 20240308

NENP Non-entry into the national phase

Ref country code: DE